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Abstract
Introduction: IntelliVent-ASV™ is a full closed-loop ventilation mode that automatically adjusts ventilation and
oxygenation parameters in both passive and active patients. This feasibility study compared oxygenation and
ventilation settings automatically selected by IntelliVent-ASV™ among three predefined lung conditions (normal
lung, acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD)) in active and
passive patients. The feasibility of IntelliVent-ASV™ use was assessed based on the number of safety events, the
need to switch to conventional mode for any medical reason, and sensor failure.
Method: This prospective observational comparative study included 100 consecutive patients who were invasively
ventilated for less than 24 hours at the time of inclusion with an expected duration of ventilation of more than 12
hours. Patients were ventilated using IntelliVent-ASV™ from inclusion to extubation. Settings, automatically selected
by the ventilator, delivered ventilation, respiratory mechanics, and gas exchanges were recorded once a day.
Results: Regarding feasibility, all patients were ventilated using IntelliVent-ASV™ (392 days in total). No safety issues
occurred and there was never a need to switch to an alternative ventilation mode. The fully automated ventilation
was used for 95% of the total ventilation time. IntelliVent-ASV™ selected different settings according to lung
condition in passive and active patients. In passive patients, tidal volume (VT), predicted body weight (PBW) was
significantly different between normal lung (n = 45), ARDS (n = 16) and COPD patients (n = 19) (8.1 (7.3 to 8.9)
mL/kg; 7.5 (6.9 to 7.9) mL/kg; 9.9 (8.3 to 11.1) mL/kg, respectively; P 0.05). In passive ARDS patients, FiO2 and
positive end-expiratory pressure (PEEP) were statistically higher than passive normal lung (35 (33 to 47)% versus 30
(30 to 31)% and 11 (8 to 13) cmH2O versus 5 (5 to 6) cmH2O, respectively; P< 0.05).
Conclusions: IntelliVent-ASV™ was safely used in unselected ventilated ICU patients with different lung conditions.
Automatically selected oxygenation and ventilation settings were different according to the lung condition,
especially in passive patients.
Trial Registration: ClinicalTrials.gov: NCT01489085
Introduction
Mechanical ventilation is widely used in intensive care
units (ICU) to support patients’ respiratory failure. Ven-
tilatory support must be adapted to each patient’s
metabolism to provide the oxygen required in the blood
(oxygenation function) and to eliminate carbon dioxide
(CO2) (ventilation function). In conventional ventilation
modes, physicians determine the oxygenation and venti-
lation settings manually. However, due to frequent
changes in the physiological needs of ICU patients,
these ventilation settings cannot be adjusted continu-
ously, as this would require a continuous presence of
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caregivers at the bedside. To address this problem, ven-
tilator management using an open-loop computerized
decision support significantly reduces morbidity in
patients with acute respiratory distress syndrome
(ARDS) [1]. Closed-loop ventilation modes that automa-
tically adjust some settings according to physiological
input [2] represent a further advance. Closed-loop venti-
lation modes make it possible to select an individualized
ventilation [3], to reduce workload [4], to improve
patient-ventilator synchrony [5], and to reduce weaning
duration in some settings [6-8].
IntelliVent-ASV™ is a further development of adaptive
support ventilation (ASV) that automatically adjusts oxy-
genation and ventilation settings in passive (absence of
spontaneous breathing activity) and active patients. Venti-
lation settings (minute volume (MV), tidal volume (VT),
and respiratory rate (RR)) are adjusted automatically to
reach a target end-tidal CO2 (PETCO2) in passive
patients and a target RR in active patients. Oxygenation
settings (inspiratory fraction of oxygen (FiO2) and posi-
tive end-expiratory pressure (PEEP)) are adjusted automa-
tically to reach a target pulse oxymetry (SpO2).
IntelliVent-ASV™ has been studied during short peri-
ods of ventilation in passive and active ICU patients
[9,10], after cardiac surgery [11], and in pediatric care
[12]. In all situations, IntelliVent-ASV™ was safe and
delivered lower VT, peak inspiratory pressure (PINSP)
and FiO2 in passive patients as compared to the con-
trolled period in conventional ventilation. Up to now
IntelliVent-ASV™ has not been used for more than 24
hours in ventilated adult ICU patients. This prospective,
observational feasibility study measured oxygenation and
ventilation settings in ICU patients ventilated with Intel-
liVent-ASV™ from inclusion to extubation or death.
The primary objective was to compare ventilation deliv-
ered among three predefined lung conditions (normal
lung, ARDS and chronic obstructive pulmonary disease
(COPD)) in active and passive phases. The hypothesis
was that IntelliVent-ASV™ automatically selects differ-
ent settings depending on the lung condition. The sec-
ondary objective was to assess the feasibility of
IntelliVent-ASV™ use defined as the number of safety
events, the need to switch to conventional mode for any
medical reason, or sensor failure.
Patients and method
This prospective, observational, comparative study was
conducted from November 2010 to September 2011 in
the 12-bed medical-surgical adult ICU of Font Pré Hos-
pital in Toulon (France). The institutional review board
approved the protocol, which was also declared at the
Commission Nationale Informatique et Liberté (CNIL),
and informed consent was obtained from each patient’s
next of kin.
Patients
Consecutive patients admitted in the ICU between
November 2010 and September 2011 were included if
they met the inclusion criteria and none of the exclusion
criteria (Table 1). Patients were mechanically ventilated
using a Hamilton-S1 ventilator (Hamilton Medical AG,
Rhäzüns, Switzerland) with IntelliVent-ASV™ software
(v1.10) using one SpO2 sensor. A heated humidifier was
used for gas conditioning.
IntelliVent-ASV™
Basic principles
IntelliVent-ASV™ is a mode in which the physician
selects the oxygenation as a target SpO2 and ventilation
as a target PETCO2 individually for each patient. Intelli-
Vent-ASV™ combines a ventilation controller that
adjust PINSP and RR and an oxygenation controller to
adjust FiO2 and PEEP. The ventilator delivers a volume-
targeted pressure-controlled breath equivalent to an
adaptive pressure control in passive patients, and an
adaptive pressure support in active patients.
At initiation, physicians have to set predicted body
weight (PBW) [13] and the clinical condition (normal
lung, ARDS, chronic hypercapnia, or brain injury). For
each clinical condition, default target ranges of PETCO2
and SpO2 are defined, which can be manually adjusted
by the user. When chronic hypercapnia and brain injury
are selected, PEEP must be manually set and the oxyge-
nation controller selects FiO2 automatically.
Safety features
Safety limits were designed in the protocol. The venti-
lation controller was deactivated in passive patients if
plateau pressure (PPLAT) increased above 35 cmH2O,
or VT/PBW above 10 mL/kg (12 mL/Kg for COPD),
or RR above 35 breath/min for more than 30 seconds
[9], or in the case of severe respiratory acidosis with
pH below 7.20 [14]. In active patients, the ventilation
controller was deactivated if RR was above 40 breaths/
min for more than 30 seconds or in case of patient’s
severe agitation. The oxygenation controller was deac-
tivated if SpO2 was below 85% for more than 1
minute.
Settings, adjustment and weaning
IntelliVent-ASV™ was used from inclusion to extubation
or death. At initiation, physicians set the patient’s
Table 1 Inclusion and noninclusion criteria.
Inclusion criteria Exclusion criteria
1. Patient invasively ventilated for less
than 24 hours
2. Expected duration of ventilation more
than 12 hours
3. Ventilator S1 available (4 out of 12
beds)
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gender and height and clinical condition (ARDS, chronic
hypercapnia, or brain injury).
Clinical condition, PETCO2 and SpO2 targets, inspira-
tory and expiratory triggers, rise time and alarm settings
were reassessed at least twice daily during the morning
and evening rounds. When arterial blood gas was mea-
sured, the end-tidal to arterial PCO2 gradient was calcu-
lated according to: PaCO2 to PETCO2. Because the
ventilation controller uses PETCO2 to adjust MV, target
PETCO2 ranges were adjusted in passive patients when
the end-tidal to arterial PCO2 gradient was above 5
mmHg. This adjustment was mostly required for
patients with severe ventilation perfusion
Sedation was performed according to the unit proto-
col. The standard unit weaning protocol was applied,
based on a daily screening of readiness to wean criteria
and a weaning trial (equivalent of a T-tube trial) mana-
ged by the nurse in charge. Weaning trial was per-
formed using PEEP of 5 cmH2O and target MV set at
25 mL/kg PBW/min, which through experience our
team found to be equivalent of pressure support (PS) of
5 to 7 cmH2O. The FiO2 controller was still active dur-
ing the weaning trial, which lasted 30 minutes. At the
end of the weaning trial, the physician in charge decided
to extubate the patient or to return to previous ventila-
tion. Patients at risk of respiratory distress after extuba-
tion received noninvasive ventilation in sequential
sessions for 24 hours [15].
Data collection
At inclusion patients were classified into one of the four
lung conditions (normal lung, acute lung injury (ALI)/
ARDS, COPD, or others) according to their medical his-
tory, chest examination, chest radiography, arterial
blood gas analysis, and any other examination result
that may have been performed. This classification was
independent from the clinical condition selected on the
ventilator. Normal lung was selected for patients with
no underlying respiratory disease, normal chest radio-
graphy, and arterial pressure of oxygen (PaO2)/FiO2
ratio of 300 mmHg or higher; ALI/ARDS as defined by
the American-European Consensus Conference [16];
COPD as defined by the ‘GOLD’ criteria [17]; others
combines chest wall stiffness patients (presence of
kyphoscoliosis, morbid obesity with a body mass index
over 35 kg/m2, or a neuromuscular disorder) and acute
respiratory failure (PaO2/FiO2 ratio of 300 mmHg or
less without the ALI/ARDS criteria from the American-
European Consensus Conference [16]).
For any given patient each ventilation day was cate-
gorized as passive or active, the latter being defined by
the patient’s spontaneous RR over 75% of the total RR.
Settings automatically selected, manual settings, ventila-
tion delivered, respiratory mechanics, and physiologic
variables were collected once a day at 7 am using the
ventilator display. Time of data collection was chosen to
be apart from nursing care and medical procedures.
Controller deactivation was defined as the need to stop
the automated function and manually adjust the settings.
All episodes of controller deactivation were recorded.
Statistical methods
Values are expressed as medians (25th to 75th interquar-
tile range). Kruskal-Wallis analysis of variance
(ANOVA) was used to compare values between each
type of lung conditions for active and passive breathing
patients. Statistical significance was assumed for P value
no greater than 0.05. Statistical analysis was performed
using SigmaStat software (version 3.5, Systat Software,
Inc., Chicago, IL, USA).
Results
During the study period, 789 patients were admitted in
the ICU of which 103 patients were included in the
study. Three patients were not analyzed (two for missing
data and one was transferred for extracorporeal mem-
brane oxygenation (ECMO) rapidly after inclusion).
Thus, 100 patients were analyzed (Figure 1). Table 2
presents patient characteristics at inclusion, lung condi-
tion and outcomes. Seventy-seven patients were venti-
lated for longer than 24 hours.
In passive and active ventilation-days, MV, VT/PBW,
PEEP, FiO2, PINSP, and RR were statistically different
based on lung condition (Table 3, Figure 2, 3, 4). In
passive ventilation days, VT/PBW was significantly dif-
ferent between normal lung, ARDS and COPD patients
(8.1 (7.3 to 8.9) mL/kg; 7.5 (6.9 to 7.9) mL/kg; 9.9
(8.3 to 11.1) mL/kg, respectively; P <0.05) (Table 4 and
Figure 2). In passive ARDS ventilation days, FiO2 and
PEEP were statistically higher than in passive normal
lung patients (35 (33 to 47)% versus 30 (30 to 31)%
and 11 (8 to 13) cmH2O versus 5 (5 to 6) cmH2O,
respectively; P < 0.05) (Table 4 and Figure 3 and 4). In
active ventilation days, VT/PBW was significantly
higher in COPD patients as compared to normal lung
and ARDS patients (9.3 (8.6 to 11.6) mL/kg; 8.4 (7.8 to
9.1) mL/kg; 8.1 (7.5 to 9.3) mL/kg, respectively; P
<0.05) (Table 5 and Figure 2). In active ARDS and
COPD ventilation days, PEEP was significantly higher
than in normal lung patients (8 (5 to 10) cmH2O, 7 (5
to 10) cmH2O, and 5 (5 to 5) cm H2O, respectively; P
<0.05) (Table 5 and Figure 4).
Regarding feasibility, all patients were ventilated using
IntelliVent-ASV™ from inclusion to extubation or death
(392 days in total) and no safety issues occurred. There
was never a medical need to switch to another ventilation
mode. The fully automated ventilation was used for 95%
of total ventilation time, and partial automated ventilation
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for 5% of ventilation time (ventilation controller alone: 4%;
oxygenation controller alone: 1%). The ventilation control-
ler was deactivated in two patients for one day because of
an increased CO2) gradient resulting in severe respiratory
acidosis. PEEP and FiO2 controllers were deactivated for
one day in seven patients because of a poor SpO2 quality
measurement (five patients in shock, one patient with
therapeutic hypothermia and one patient with severe
chronic arterial disease). PEEP controller was deactivated
in three patients; one COPD for manual adjustment
according to intrinsic PEEP, one after a pneumothorax
resulting from subclavicular catheter insertion and one
ARDS patient for manual adjustment according to trans-
pulmonary pressure. The FiO2 controller was deactivated
in one COPD patient because of hyperoxia.
Discussion
This observational study measured ventilation and
oxygenation parameters automatically determined by
IntelliVent-ASV™ in 100 unselected ventilated ICU
patients. IntelliVent-ASV™ automatically selected differ-
ent ventilation and oxygenation parameters according to
lung condition especially for passive breathing patients.
It was feasible to use IntelliVent-ASV™ with no result-
ing safety issues for patients and with very few sensor
failures.
In passive patients, ventilation and oxygenation para-
meters determined by IntelliVent-ASV™ were different
according to lung condition. In normal lung patients, VT/
PBW was 8.1 (7.3 to 8.9) mL/kg with PPLAT at 18 (17 to
20) cmH2O and a PEEP at 5 (5 to 6) cmH2O. Current
recommendations regarding normal lung patients are to
set VT/PBW between 6 and 8 mL/kg in patients at risk
of ARDS, and ≤10 mL/kg in patients without risk factors
and to set PEEP between 5 and 12 cmH2O [18,19]. Thus,
ventilation selected by IntelliVent-ASV™ in patients with
normal lungs at the onset of mechanical ventilation is in
line with current recommendations to prevent ventilator-
Figure 1 Study flow diagram.
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induced lung injuries (VILI). FiO2 selected in passive nor-
mal lung patients was 30 (30 to 31)%. A recent retrospec-
tive database study found that hyperoxia is commonly
seen in the ICU and in most cases does not lead to the
adjustment of ventilator settings if FiO2 is below or equal
to 40% [20]. There have been studies in humans that
report the physiological effects of hyperoxia including
impaired myocardial blow flow [21], increased myocardial
consumption [22], and reduced cerebral blood flow due
to arterial vasoconstriction [23]. Thus, in normal lung
patients, where hyperoxia is easily obtained, automatic
adjustment of FiO2 should minimize FiO2 levels, prevent
unnecessary hyperoxia and avoid potential systemic oxy-
gen toxicity.
In passive ARDS patients, VT/PBW was 7.5 (6.1 to
8.8) mL/kg with PPLAT at 26 (23 to 29) cmH2O and a
PEEP at 11 (8 to 13) cmH2O. These results are in line
with current recommendations to use a protective venti-
lation strategy in order to prevent VILI. A meta-analysis
of protective ventilation trials in ARDS patients found a
favorable effect for VT/PBW less than 7.7 mL/kg [24].
Even though PPLAT and VT/PBW are not good surro-
gates to assess lung stress and strain [25], these values
are easily measured at the bedside and are widely used.
A large international observational study showed that
the current mechanical ventilation practice in ARDS
patients is to set a median VT/PBW between 6 and 8
mL/kg with a median PEEP at 5 to 12 cmH2O [26]. A
large multicenter observational study in Spain observed
255 ARDS patients and found a VT/PBW at 7.2 ± 1.1
mL/kg, PPLAT at 26 ± 5 cmH2O, and PEEP at 9.3 ± 2.4
cmH2O [27]. Thus, IntelliVent-ASV
™ selects VT/PBW
and PEEP that are in line with current recommenda-
tions and current practices. Despite the evidence show-
ing that a reduced VT strategy is associated with
improved outcomes, physicians still routinely use higher
VT than recommended [28-30]. The main reasons for
physicians’ underuse of low VT ventilation are the use of










P (ANOVA) Post hoc comparison (P ≤0.05)
Number of patients 45 16 19 20
Number of days 139 90 79 84
MV (L/min) 9.3 (7.5-11.7) 9.7 (7.8-13.3) 9.4 (6.4-11.9) 7.5 (6.6-10.8) 0.001 1 vs. 4
VT/PBW (mL/kg) 8.3 (7.7-9.1) 7.8 (7.2-8.5) 9.4 (8.4-11.5) 8.0 (7.3-9.2) <0.001 1 vs. 3; 2 vs. 3; 3 vs. 4
PEEP (cmH2O) 5 (5-6) 9 (5-12) 7 (5-10) 8 (5-11) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4
FiO2 (%) 30 (30-30) 34 (30-43) 31 (30-36) 30 (30-41) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4; 2 vs. 3
PINSP (cmH2O) 21 (18-25) 25 (20-30) 24 (19-38) 26 (22-30) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4
RR (breath/min) 19 (16-23) 20 (16-26) 15 (12-19) 18 (14-22) <0.001 1 vs. 3; 2 vs. 3; 2 vs. 4
RCEXP (s) 0.61 (0.50-0.75) 0.50 (0.43-0.58) 0.91 (0.64-1.22) 0.56 (0.46-0.66) <0.001 1 vs. 2; 1 vs. 3; 2 vs. 3; 3 vs. 4
PaO2/FiO2 (mm Hg) 326 (267-380) 206 (172-252) 260 (206-328) 241 (189-304) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4; 2 vs. 3; 2 vs. 4
PaO2 (mm Hg) 100 (85-117) 76 (69-84) 86 (74-105) 82 (73-95) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4; 2 vs. 3; 2 vs. 4
pH 7.36 (7.30-7.41) 7.35 (7.23-7.42) 7.30 (7.25-7.35) 7.33 (7.26-7.41) <0.001 1 vs. 3; 2 vs. 3
PaCO2 (mm Hg) 35 (31-40) 41 (35-49) 45 (37-53) 39 (34-46) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4
Values represent the median of all data. Comparisons used a Kruskal-Wallis analysis of variance (ANOVA) with a Dunn’s post hoc test. MV, minute volume, VT/
PBW, tidal volume on predicted body weight ratio, PEEP, positive end-expiratory pressure, PINSP, peak inspiratory pressure, RR, respiratory rate, RCEXP, expiratory
time constant, vs., versus.
Table 2 Baseline characteristics of the study population,
lung condition at inclusion, and outcomes.
Number of patients 100
Age (years) 73 (64-79)
Gender (M/F) 58/42
Actual body weight (kg) 85 (60-80)
Predicted body weight (kg) 60 (53-68)
SAPS II 56 (48-69)
Mechanical ventilation duration before inclusion (days) 0.5 (0.0-0.8)
Sedation at inclusion (n) 73
Vasopressors at inclusion (n) 52
Passive ventilation duration (days) 1.0 (0.0-2.5)
Active mechanical ventilation duration (days) 1.2 (0.5-3.0)
Duration of invasive mechanical ventilation (days) 3.0 (2.0-7.0)
Post-extubation noninvasive mechanical ventilation (n) 26
Total duration of mechanical ventilation (days) 4.0 (2.0-7.0)
Reintubation (n) 2
Duration of ICU stay (days) 5 (2-10)
Duration of hospital stay (days) 11 (4-22)
ICU mortality (n) 31
Hospital mortality (n) 41
Data are presented as median (25th to 75th quartile). SAPS, simplified acute
physiology score.
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Figure 2 Tidal volume selected by IntelliVent-ASV™: Tidal volume on predicted body weight ratio for normal lung patients, ARDS and
COPD patients. For each lung condition, all patients, passive patients and active patients are shown on the left, middle and right box plot,
respectively. Comparisons used a Kruskal-Wallis analysis of variance with a Dunn’s post hoc test. *P ≤0.05. ARDS, acute respiratory distress
syndrome; COPD, chronic obstructive pulmonary disease.
Figure 3 FiO2 selected by IntelliVent-ASV
™: FiO2 for normal lung patients, ARDS and COPD patients. For each lung condition, all patients,
passive patients and active patients are shown on the left, middle and right box plot, respectively. Comparisons used a Kruskal-Wallis analysis of
variance with a Dunn’s post hoc test. *P ≤0.05. ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; FiO2,
inspiratory fraction of oxygen (%).
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Figure 4 PEEP selected by IntelliVent-ASV™: PEEP for normal lung patients, ARDS and COPD patients. For each lung condition, all
patients, passive patients and active patients are shown on the left, middle and right box plot, respectively. Comparisons used a Kruskal-Wallis
analysis of variance with a Dunn’s post hoc test. *P ≤0.05. ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary
disease; PEEP, positive end-expiratory pressure (cmH2O).










P (ANOVA) Post hoc comparison (P ≤ 0.05)
Number of patients 27 13 12 15
Number of days 63 36 23 40
MV (L/min) 8.4 (6.73-9.7) 7.9 (6.1-8.8) 7.8 (5.3-9.0) 7.2 (5.3-8.5) 0.076
VT/PBW (mL/kg) 8.1 (7.3-8.9) 7.5 (6.9-7.9) 9.9 (8.3-11.1) 8.0 (7.5-9.2) <0.001 1 vs. 2; 1 vs. 3; 2 vs. 3; 2 vs. 4
PEEP (cmH2O) 5 (5-6) 11 (8-13) 8 (5-15) 10 (5-13) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4
FiO2 (%) 30 (30-31) 35 (33-47) 31 (30-38) 31 (30-53) <0.001 1 vs. 2; 1 vs. 4
PINSP (cmH2O) 21 (19-23) 27 (24-30) 27 (23-39) 26 (23-30) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4
RR (breath/min) 17 (15-21) 16 (15-20) 13 (12-15) 15 (13-18) <0.001 1 vs. 3; 1 vs. 4; 2 vs. 3
RCEXP (s) 0.58 (0.50-0.72) 0.47 (0.40-0.54) 1.22 (0.68-1.37) 0.57 (0.46-0.72) <0.001 1 vs. 2; 1 vs. 3; 2 vs. 3; 2 vs. 4; 3 vs. 4
RINSP (cm H2O/s/L) 15 (12-17) 11 (10-16) 21 (17-26) 16 (12-20) <0.001 1 vs. 3; 2 vs. 3; 2 vs. 4
CSTAT (L/cm H2O) 39 (35-54) 29 (26-37) 53 (46-61) 32 (28-40) <0.001 1 vs. 2; 1 vs. 4; 2 vs. 3; 3 vs. 4
I/E ratio 0.61 (0.43-0.77) 0.91 (0.83-1.00) 0.43 (0.32-0.50) 0.77 (0.61-1.00) <0.001 1 vs. 2; 2 vs. 3; 3 vs. 4
PPLAT (cm H2O) 18 (17-20) 26 (23-29) 23 (17-31) 24 (21-28) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4
PaO2/FiO2 (mm Hg) 328 (264-366) 201 (155-256) 253 (206-295) 208 (147-301) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4
PaO2 (mm Hg) 99 (85-114) 74 (66-88) 83 (77-94) 82 (70-95) <0.001 1 vs. 2; 1 vs. 4
pH 7.33 (7.27-7.40) 7.24 (7.15-7.34) 7.29 (7.20-7.31) 7.29 (7.22-7.34) 0.002 1 vs. 2; 1 vs. 3
PaCO2 (mm Hg) 38 (35-42) 49 (45-57) 49 (44-67) 43 (38-51) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4; 2 vs. 4; 3 vs. 4
Values represent the median of all data. Comparisons used a Kruskal-Wallis analysis of variance (ANOVA) with a Dunn’s post hoc test. MV, minute volume, VT/
PBW, tidal volume on predicted body weight ratio, PEEP, positive end-expiratory pressure, PINSP, peak inspiratory pressure, RR, respiratory rate, RCEXP, expiratory
time constant, RINSP, inspiratory resistances, CSTAT, static compliance, I/E, inspiratory on expiratory time ratio, PPLAT, plateau pressure, vs., versus.
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actual body weight instead of PBW in the calculation of
VT, a general underrecognition of ARDS in clinical prac-
tice [31], physician concern about increasing RR with a
potential risk of dynamic hyperinflation [32], and con-
cern about permissive hypercapnia and acidosis [33].
IntelliVent-ASV™ automatically computes the PBW
based on height and gender, automatically recognizes
short expiratory time constant (RCEXP) and adjusts VT
and RR accordingly, prevents dynamic hyperinflation in
passive patients by adjusting expiratory time according
to RCEXP, and allows a moderate permissive hypercapnia
when PINSP is above 25 cmH2O. Overall, IntelliVent-
ASV™ is a useful way to help implement protective
ventilation.
In ARDS patients, IntelliVent-ASV™ selected oxygena-
tion settings that combined a moderately high PEEP (11
(8 to 13) cmH2O) with a low FiO2 (35 (33 to 47)%).
This combination follows the higher PEEP-FiO2 table
[34], which complies with the open lung concept [35] in
order to prevent atelectrauma.
In passive COPD patients, VT/PBW was 9.9 (8.3 to
11.1) mL/kg. There is no consensus as to the optimal
VT in passive COPD [36,37]. However, because end-
expiratory lung volume is increased in COPD, the lung
strain associated with relatively high VT remains limited
[25].
In active patients, the difference in VT/PBW between
each lung condition was less than in passive patients.
This is explained by the range of RCEXP, which was nar-
rower in the lung conditions in active compared to pas-
sive patients. As a consequence, there is not a
significant difference between the target VT/PBW deter-
mined by the ASV algorithm for the different lung con-
ditions. In addition, VT/PBW in active patients is very
dependent on patient’s drive, which may be increased as
a result of elements such as metabolic acidosis, pain,
discomfort, anxiety, and the sedation used. It should be
noted that active ARDS patients are in the weaning
phase after severe hypoxemia has been resolved.
In this study, assessment of feasibility was defined by
the number of safety events, the need to switch to
another mode and sensor failure. As in previous studies
[9-11], there was no safety issue according to the prede-
fined safety criteria. None of the users were uncomforta-
ble with IntelliVent-ASV™ to the extent that it was
necessary to switch to conventional ventilation. Overall,
physicians had to deactivate one controller for only 5%
of the total ventilation time. The main reasons were a
large CO2 gradient and SpO2 signal of poor quality
[38,39]. Considering the large numbers of ventilation
days and the relatively small number of problems, this
study shows that the use of IntelliVent-ASV™ is feasible
on a daily basis in unselected ICU patients with different
lung conditions. However, monitoring of patients is still
required, especially for the CO2 gradient in patients
with large ventilation/perfusion ratio disturbances. Also,
in case of sudden decrease of PETCO2 due to a shock
or pulmonary embolism, there is a risk of hypoventila-
tion. The current software does not sound an alarm
when PETCO2 and MV change but does sound an
alarm when the low PETCO2 or MV threshold is
reached.










P (ANOVA) Post hoc comparison (P ≤0.05)
Number of patients 33 13 18 15
Number of days 76 54 57 44
MV (L/min) 10.1 (8.0-13.0) 12.5 (11.0-14.9) 11.1 (8.3-13.9) 9.2 (7.2-12.0) <0.001 1 vs. 2; 2 vs.
VT/PBW (mL/kg) 8.4 (7.8-9.1) 8.1 (7.5-9.3) 9.3 (8.6-11.6) 7.7 (7.2-9.3) <0.001 1 vs. 3; 2 vs. 3; 3 vs. 4
PEEP (cmH2O) 5 (5-5) 8 (5-10) 7 (5-10) 7 (5-10) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4
FiO2 (%) 30 (30-30) 33 (30-38) 30 (30-33) 30 (30-34) <0.001 1 vs. 2
PINSP (cmH2O) 21 (16-26) 24 (16-28) 22 (17-36) 24 (21-28) 0.052
RR (breath/min) 21 (18-26) 25 (20-29) 18 (14-20) 21 (17-26) <0.001 1 vs. 3; 2 vs. 3; 3 vs. 4
RCEXP (s) 0.66 (0.51-0.78) 0.52 (0.45-0.61) 0.86 (0.64-1.12) 0.53 (0.46-0.65) <0.001 1 vs. 2; 1 vs. 3; 2 vs. 3; 3 vs. 4
PaO2/FiO2 (mm Hg) 322 (278-387) 213 (173-250) 273 (206-341) 253 (222-311) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4; 2 vs. 3; 2 vs. 4
PaO2 (mm Hg) 102 (85-121) 77 (70-84) 89 (72-107) 83 (75-94) <0.001 1 vs. 2; 1 vs. 3; 1 vs. 4; 2 vs. 3
pH 7.38 (7.34-7.44) 7.40 (7.35-7.43) 7.33 (7.25-7.37) 7.37 (7.30-7.42) <0.001 1 vs. 3; 2 vs. 3; 3 vs. 4
PaCO2 (mm Hg) 32 (28-37) 37 (30-40) 41 (34-50) 36 (32-44) <0.001 1 vs. 3; 1 vs. 4
Values represent the median of all data. Comparisons used a Kruskal-Wallis analysis of variance (ANOVA) with a Dunn’s post hoc test. MV, minute volume, VT/
PBW, tidal volume on predicted body weight ratio, PEEP, positive end-expiratory pressure, PINSP, peak inspiratory pressure, RR, respiratory rate, RCEXP, expiratory
time constant, vs., versus.
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The main limitation of this study is that it is observa-
tional, which does not allow comparison with conven-
tional modes in terms of settings or outcome. In
addition, numbers of severe ARDS patients were too
small to draw definitive conclusions on safety. Studies in
this subgroup population are required. Data were col-
lected once a day and not continuously. Results would
possibly be different if measured continuously or with a
higher sampling rate. However, the times that were
selected to collect the data were chosen specifically to
be isolated from nursing care and medical procedures.
Adaptation of IntelliVent-ASV™ during nursing care
and medical procedures deserves additional studies.
Finally, this study was performed in a unit with a large
experience of ASV use. Applicability of results may be
different in other settings.
Conclusions
This observational study found that IntelliVent-ASV™
seems safe for all ICU duration in ventilated unselected
ICU patients with different lung conditions. More data
is required for specific populations, in particular severe
ARDS patients. Automatically selected oxygenation and
ventilation settings were different according to the lung
condition, especially in passive patients, and are in line
with current recommendations. These results are a step
forward in the implementation of closed-loop mode in
daily practice in the ICU.
Key messages
• Use of a full closed-loop ventilation mode seems
safe in nonselected ICU patients.
• The full closed-loop ventilation mode can be used
during 95% of the total ventilation time.
• IntelliVent-ASV™ selects different ventilation and
oxygenation settings in passive and active patients
with normal lungs, ARDS, and COPD.
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